Intensity Therapeutics, Inc. (INTS)
NASDAQ: INTS · Real-Time Price · USD
0.4020
+0.0060 (1.52%)
Jan 6, 2026, 9:41 AM EST - Market open
Intensity Therapeutics Employees
As of December 31, 2024, Intensity Therapeutics had 7 total employees, including 5 full-time and 2 part-time employees. The number of employees did not change compared to the previous year.
Employees
7
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,676,571
Market Cap
24.15M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 7 | 0 | - |
| Dec 31, 2023 | 7 | 1 | 16.67% |
| Dec 31, 2021 | 6 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
INTS News
- 26 days ago - Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium - PRNewsWire
- 4 weeks ago - Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement - PRNewsWire
- 4 weeks ago - Intensity Therapeutics Announces Two Presentations at the Upcoming 2025 San Antonio Breast Cancer Symposium - PRNewsWire
- 2 months ago - Intensity Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - PRNewsWire
- 2 months ago - Intensity Therapeutics, Inc. (INTS) Discusses eBioMedicine Paper Study Results and Underlying Technology Transcript - Seeking Alpha
- 2 months ago - Intensity Therapeutics, Inc. Announces Pricing of $4 Million Registered Direct Offering of Common Stock - PRNewsWire
- 2 months ago - Intensity Therapeutics, Inc. Announces Publication of Clinical Results of INT230-6 for the Treatment of Metastatic or Refractory Cancers in eBioMedicine, a Lancet Discovery Science Journal - PRNewsWire
- 4 months ago - Intensity Therapeutics Reports INVINCIBLE-4, Presurgical Triple-Negative Breast Cancer Study Update - PRNewsWire